CY2017025I1 - Αντιδοτα αντιπηκτικων - Google Patents

Αντιδοτα αντιπηκτικων

Info

Publication number
CY2017025I1
CY2017025I1 CY2017025C CY2017025C CY2017025I1 CY 2017025 I1 CY2017025 I1 CY 2017025I1 CY 2017025 C CY2017025 C CY 2017025C CY 2017025 C CY2017025 C CY 2017025C CY 2017025 I1 CY2017025 I1 CY 2017025I1
Authority
CY
Cyprus
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
Prior art date
Application number
CY2017025C
Other languages
English (en)
Other versions
CY2017025I2 (el
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY2017025I1 publication Critical patent/CY2017025I1/el
Publication of CY2017025I2 publication Critical patent/CY2017025I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
CY2017025C 2010-01-20 2017-07-10 Αντιδοτα αντιπηκτικων CY2017025I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10151239 2010-01-20
US38391410P 2010-09-17 2010-09-17
PCT/EP2011/050749 WO2011089183A2 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes
EP11703410.8A EP2525812B1 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes

Publications (2)

Publication Number Publication Date
CY2017025I1 true CY2017025I1 (el) 2017-11-14
CY2017025I2 CY2017025I2 (el) 2017-11-14

Family

ID=42061991

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100361T CY1118875T1 (el) 2010-01-20 2017-03-22 Αντιδοτα αντιπηκτικων
CY2017025C CY2017025I2 (el) 2010-01-20 2017-07-10 Αντιδοτα αντιπηκτικων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100361T CY1118875T1 (el) 2010-01-20 2017-03-22 Αντιδοτα αντιπηκτικων

Country Status (43)

Country Link
US (3) US8486398B2 (el)
EP (2) EP3195876A1 (el)
JP (2) JP5575923B2 (el)
KR (1) KR101781787B1 (el)
CN (1) CN102711813B (el)
AP (1) AP2012006242A0 (el)
AR (1) AR079944A1 (el)
AU (1) AU2011208719C1 (el)
BR (1) BR112012018021B1 (el)
CA (1) CA2787566A1 (el)
CO (1) CO6571889A2 (el)
CY (2) CY1118875T1 (el)
DK (1) DK2525812T3 (el)
EA (1) EA028371B1 (el)
EC (1) ECSP12012105A (el)
ES (1) ES2614992T3 (el)
FR (1) FR17C1026I2 (el)
GE (1) GEP20156341B (el)
HK (1) HK1173957A1 (el)
HR (1) HRP20170613T1 (el)
HU (2) HUE032263T2 (el)
IL (1) IL219427B (el)
LT (2) LT2525812T (el)
LU (1) LUC00028I2 (el)
MA (1) MA33936B1 (el)
ME (1) ME02602B (el)
MX (1) MX2012008360A (el)
MY (1) MY162323A (el)
NL (1) NL300882I2 (el)
NO (2) NO2017034I1 (el)
NZ (1) NZ599508A (el)
PE (1) PE20121516A1 (el)
PL (1) PL2525812T3 (el)
PT (1) PT2525812T (el)
RS (1) RS55683B1 (el)
SG (1) SG182552A1 (el)
SI (1) SI2525812T1 (el)
TN (1) TN2012000366A1 (el)
TW (1) TWI513466B (el)
UA (1) UA110470C2 (el)
UY (1) UY33196A (el)
WO (1) WO2011089183A2 (el)
ZA (1) ZA201202876B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CA2824885A1 (en) * 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN103476459A (zh) * 2011-03-30 2013-12-25 勃林格殷格翰国际有限公司 抗凝血剂解毒剂
US9522892B2 (en) 2011-11-29 2016-12-20 Perosphere Inc. Anticoagulant reversal agents
EP2970500A1 (en) 2013-03-14 2016-01-20 Bayer HealthCare LLC Monoclonal antibodies against antithrombin beta complexed with heparin
WO2015059159A1 (en) * 2013-10-25 2015-04-30 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) * 2014-05-26 2016-01-06 北京九强生物技术股份有限公司 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
JP6776221B2 (ja) * 2014-07-31 2020-10-28 ヘモネティクス・コーポレーションＨａｅｍｏｎｅｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 凝固分析を使用した抗凝固剤の検出および分類
WO2016044645A1 (en) * 2014-09-17 2016-03-24 Elmaleh David R Anticoagulant derivatives for cardiovascular imaging
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
AU2018388079A1 (en) * 2017-12-24 2020-07-16 Noile-Immune Biotech, Inc. Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, IL-7 and CCL19
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
WO2019217705A1 (en) * 2018-05-11 2019-11-14 Proplex Technologies, LLC Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
KR20210086682A (ko) 2018-10-29 2021-07-08 화하이 유에스 인코퍼레이티드 신규한 디펩티드 화합물과 이의 용도
US20220175748A1 (en) 2019-03-06 2022-06-09 University Of Rochester Anticoagulant compositions and uses thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) * 2021-08-02 2023-06-01 日商諾伊爾免疫生物科技股份有限公司 與scFv等之連接子結合的抗體
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69309472T2 (de) * 1992-01-23 1997-10-23 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
DE19729544A1 (de) * 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
PL364623A1 (en) 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
KR102271404B1 (ko) * 2007-09-28 2021-07-02 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
ES2436076T3 (es) 2009-08-24 2013-12-26 Boehringer Ingelheim International Gmbh Intervenciones de urgencia de carbón vegetal activo con sobredosificación con etexilato de dabigatrán
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
GEP20156341B (en) 2015-08-10
NL300882I2 (nl) 2017-07-20
ZA201202876B (en) 2012-12-27
JP2013517317A (ja) 2013-05-16
LTPA2017021I1 (lt) 2017-07-25
MA33936B1 (fr) 2013-01-02
LUC00028I1 (el) 2017-07-14
US20120027780A1 (en) 2012-02-02
WO2011089183A3 (en) 2011-11-17
KR20120128126A (ko) 2012-11-26
KR101781787B1 (ko) 2017-09-26
IL219427B (en) 2018-05-31
JP2014210794A (ja) 2014-11-13
US20130289248A1 (en) 2013-10-31
CN102711813A (zh) 2012-10-03
UY33196A (es) 2011-08-31
AP2012006242A0 (en) 2012-04-30
WO2011089183A2 (en) 2011-07-28
US20150210778A1 (en) 2015-07-30
HUS1700030I1 (hu) 2017-08-28
AU2011208719A1 (en) 2012-05-17
TW201136606A (en) 2011-11-01
EP2525812A2 (en) 2012-11-28
HUE032263T2 (en) 2017-09-28
LT2525812T (lt) 2017-02-27
DK2525812T3 (en) 2017-02-27
HK1173957A1 (en) 2013-05-31
AR079944A1 (es) 2012-02-29
TWI513466B (zh) 2015-12-21
RS55683B1 (sr) 2017-07-31
BR112012018021A2 (pt) 2017-06-20
ME02602B (me) 2017-06-20
JP5575923B2 (ja) 2014-08-20
FR17C1026I1 (fr) 2017-09-08
CY2017025I2 (el) 2017-11-14
EP3195876A1 (en) 2017-07-26
NO2022036I1 (no) 2022-08-12
HRP20170613T1 (hr) 2017-06-30
LUC00028I2 (el) 2017-09-25
CA2787566A1 (en) 2011-07-28
US9034822B2 (en) 2015-05-19
MX2012008360A (es) 2012-08-08
PL2525812T3 (pl) 2017-07-31
MY162323A (en) 2017-05-31
CY1118875T1 (el) 2018-01-10
BR112012018021B1 (pt) 2020-12-08
NZ599508A (en) 2014-05-30
AU2011208719C1 (en) 2017-07-13
CN102711813B (zh) 2015-03-04
LTC2525812I2 (lt) 2019-05-10
TN2012000366A1 (en) 2014-01-30
EA201201016A1 (ru) 2013-02-28
ES2614992T3 (es) 2017-06-02
EP2525812B1 (en) 2017-01-18
US8486398B2 (en) 2013-07-16
UA110470C2 (ru) 2016-01-12
SI2525812T1 (sl) 2017-05-31
PE20121516A1 (es) 2012-11-24
PT2525812T (pt) 2017-04-26
FR17C1026I2 (fr) 2018-07-20
NO2017034I1 (no) 2017-07-11
EA028371B1 (ru) 2017-11-30
SG182552A1 (en) 2012-08-30
IL219427A0 (en) 2012-06-28
ECSP12012105A (es) 2012-10-30
CO6571889A2 (es) 2012-11-30

Similar Documents

Publication Publication Date Title
CY2017025I1 (el) Αντιδοτα αντιπηκτικων
DK2585140T3 (da) Autoinjektor
BR112013008072A2 (pt) autoinjetor
BR112013008401A2 (pt) autoinjetor
DK2536452T3 (da) Autoinjektor
DK2585137T3 (da) Autoinjektor
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
DK2654833T3 (da) Autoinjektor
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DK2654842T3 (da) Autoinjektor
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
CO6771448A2 (es) Antídotos anticoagulantes
DE102011002623A8 (de) Ventilsteuerzeitversteller
DK2567097T3 (da) Centrifugalpumpe
DE112011102711A5 (de) Hydrostataktor
DE102010019119B8 (de) Cuttermesser
BR112013015785A2 (pt) autoinjetor
DE112010005518A5 (de) Dichtungsmanchette
DE102010038420A8 (de) Reinigungungsvorrichtung
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
DE112011101796A5 (de) Redoxakkumulatoranlage